Pr. John Krystal joins ReST SAB

ReST Therapeutics announces that Pr. John Krystal has joined its Scientific Advisory Board ReST Therapeutics, clinical-stage biotech company developing breakthrough therapies to treat Alzheimer Disease (AD) and Post-Traumatic Stress Disorder (PTSD), today announced...

EMA endorses ReST FIH for FENM

ReST Therapeutics announces the endorsement by the European Medicine Agency (EMA) to enter the clinical phase and request First in Human (FIH) administration of its drug candidate FENM. ReST Therapeutics, clinical-stage biotech company developing breakthrough...

USPTO grants ReST Therapeutic’s Patent on PTSD

On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST Therapeutics’  project is to develop a proprietary drug candidate for the treatment of  Post-Traumatic Syndrome and...